Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib plus thoracic radiotherapy versus icotinib alone in EGFR-mutant advanced non-small cell lung cancer
ChiCTR-IIR-16007769Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of icotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: progression-free survival and side effects. Started Dec 2015; status: recruiting.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-16007769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007769.